human ace2

MLN-4760 is an angiotensin-converting (ACE2) inhibitor(human ACE2;IC50=0.44 nM). It also has excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM).

SSAA09E2 is a new SARS-CoV replication inhibitor, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2).

SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV, demonstrating in vivo anti-infection activity. It interferes with the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) with an EC50 of 26.5 μM, effectively blocking SARS-CoV-2 entry into VeroE6 cells (ECS50=17.0 μM). The compound has a CC50 greater than 100 μM in VeroE6 cells.

CK2-IN-15 (Compound Biv5) is a selective and potent inhibitor of the enzyme protein kinase CK2, with an IC50 value of 51 pM. It significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also decreases viral replication in an in vitro model of human nasal epithelial cells. CK2-IN-15 holds potential for research into diseases related to β-coronavirus infections.

Anti-Spike-RBD mAb is a CHO cell-derived human monoclonal IgG1 antibody that potentially treats SARS-CoV-2 by blocking the interaction between the spike protein and ACE2[1].

Human ACE2 receptor-derived 23-amino acid peptide. Binds receptor binding domain (RBD) of insect-derived SARS-CoV-2 spike protein (KD = 1.3 μM for N-terminal biotinylated, insect-derived spike protein RBD; see Zhang et al preprint publication). Please note - unpublished, in-house data suggests approximately 75-fold lower affinity for insect-derived SARS-CoV-2 RBD than reported by Zhang et al.

Fluorescently labelled peptide derived from human ACE2 (SBP1, Cat. No. 7233). Composed of SBP1 conjugated to FITC (Fluorescein-5-isothiocyanate; Cat. No. 5440). SBP1 binds receptor binding domain (RBD) of insect-derived SARS-CoV-2 spike protein (KD = 1.3 μM for N-terminal biotinylated, insect-derived spike protein RBD; see Zhang et al preprint publication). Please note - unpublished, in-house data suggests SBP1 has approximately 75-fold lower affinity for insect-derived SARS-CoV-2 RBD than reported by Zhang et al.

Adintrevimab is an engineered human IgG1 monoclonal antibody, which targets the conserved epitope in the receptor binding domain (RBD) of spike protein of SARS-like coronavirus, thus blocking its binding with ACE2 receptor and playing a broad-spectrum neutralization role. Adintrevimab has strong activity against many SARS-CoV-2 variants, but its neutralizing ability is obviously decreased in some Omicron subtypes.

Bebtelovimab (LY-CoV1404) is a neutralizing, fully human IgG1 monoclonal antibody targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. This product binds specifically to a highly conserved epitope on the RBD, blocking the interaction between the spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor. Bebtelovimab exhibits potent and broad neutralizing activity against various SARS-CoV-2 variants, including Omicron (BA.1/BA.2), Delta, and other earlier strains. In clinical settings, it is utilized to reduce the risk of severe disease progression in high-risk ambulatory patients, such as solid organ transplant recipients.

CMX990, a SARS-CoV-2 3CL protease inhibitor, exhibits EC90 values of 9.6 nM in human bronchial epithelial cells (HBECs) and 101 nM in HeLa-ACE2 cells. It also demonstrates good ADME and pharmacokinetic properties [1].

VIR-7229 is a human IgG1 monoclonal antibody that targets the Receptor-Binding Domain (RBD) of the Spike glycoprotein. It exhibits antiviral activity by competing with ACE2 for binding and inducing the shedding of the S1 protein. VIR-7229 is applicable for research on SARS-CoV-2 infections. Recommended isotype control: Human IgG1 kappa, Isotype Control.

Canvircept is a recombinant fusion protein comprised of angiotensin-converting enzyme 2 (ACE2) linked to the human IgG1 Fc region.

Anti-ACE2 Antibody (1Y227) is a Mouse IgG1 monoclonal antibody targeting Human ACE2.

Anti-ACE2 Antibody (7D640) is a Mouse IgG1 monoclonal antibody targeting Human ACE2.